Search
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[A222398] Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola. … [A222393] Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017,[A191382] leading to considerable interest in remdesivir as a possible treatment for COVID-19.
Perboric acid
go.drugbank.com/drugs/DB13235Approved[A33037] It is one of the peroxy acid salts with very wide functionalities in industrial settings. … Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate.
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Prezatide
go.drugbank.com/drugs/DB11296ApprovedPrezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions
Categories: Compounds used in a research, industrial, or household settingFexinidazole
go.drugbank.com/drugs/DB12265Approved[A237550, A237560] Fexinidazole, which was originally developed in the 1970s/80s by Hoechst AG and subsequently rediscovered through the Drugs for Neglected Diseases Initiative (DNDi) in 2005, is the first … [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.
Trofinetide
go.drugbank.com/drugs/DB06045Approved[A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … , making trofinetide the first and only treatment approved for Rett syndrome in the European Union.
Mivacurium
go.drugbank.com/drugs/DB01226ApprovedWithdrawnIt binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Iodixanol
go.drugbank.com/drugs/DB01249ApprovedIodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the
Categories: Compounds used in a research, industrial, or household settingSynonyms: 5,5'-((2-hydroxytrimethylene)bis(acetylimino))bis(N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)Potassium citrate
go.drugbank.com/drugs/DB09125ApprovedInvestigationalVet approvedIn the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis.
Mixtures: Children's Chewable Vit and Min Tab, PEDIALYTE®30MEQ CON ZN